Titrating Growth Hormone Dose to High-Normal IGF-1 Levels Has Beneficial Effects on Body Fat Distribution and Microcirculatory Function Despite Causing Insulin Resistance

What Was Tested

The paper reports a study of IGF-1 LR3 in the context of insulin resistance, prediabetes & type 2 diabetes, published as a randomized controlled trial.

This change was related to the favorable change in waist circumference.

Who Took Part

According to the abstract, 30 subjects were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and parallel-group study.

Because people in this IGF-1 LR3 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The IGF-1 LR3 group and the comparison group ran side by side rather than switching.

Microvascular endothelium (in)dependent vasodilatation and vasomotion, vascular stiffness by pulse wave analysis, and HOMA-IR were measured.

What Was Measured

Topics PubMed links to this paper include Body Composition, Body Fat Distribution, Human Growth Hormone, Insulin Resistance, Insulin-Like Growth Factor I, Microcirculation and Waist Circumference.

The authors tagged it with the keywords growth hormone deficiency in adults, growth hormone treatment, insulin-like growth factor-1, vascular endothelium and vasomotion.

What This Means in Plain Language

The paper is a randomized and parallel-group study of IGF-1 LR3 in 30 subjects in people with insulin resistance, prediabetes & type 2 diabetes.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2020 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the IGF-1 LR3 compound page, Insulin resistance, prediabetes & type 2 diabetes research.